Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × lenvatinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 123 Carcinoma, Renal Cell 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 25 Neoplasms 24 Cholangiocarcinoma 24 Endometrial Neoplasms 16 Thyroid Neoplasms 15 Liver Neoplasms 15 Melanoma 13 Biliary Tract Neoplasms 10 Stomach Neoplasms 9 Recurrence 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 7 Ovarian Neoplasms 7 Neoplasm Metastasis 7 Breast Neoplasms 7 Uterine Cervical Neoplasms 5 Small Cell Lung Carcinoma 5 Triple Negative Breast Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Transitional Cell 4 Thyroid Carcinoma, Anaplastic 3 Solid Tumors 3 Pancreatic Neoplasms 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Carcinoma, Ovarian Epithelial 3

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07096609 2025-07-31

LONGIST

Asan Medical Center

Phase 1/2 Not yet recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡